Cargando…

Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice

In the AMPLIFY clinical trial, apixaban was non-inferior to warfarin plus subcutaneous enoxaparin bridge therapy in the treatment of acute venous thromboembolism (VTE) and was associated with significantly less bleeding. This study evaluated their comparative effectiveness and safety in routine clin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weycker, Derek, Li, Xiaoyan, Wygant, Gail DeVecchis, Lee, Theodore, Hamilton, Melissa, Luo, Xuemei, Vo, Lien, Mardekian, Jack, Pan, Xianying, Burns, Leah, Atwood, Mark, Hanau, Ahuva, Cohen, Alexander T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2018
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206509/ https://www.ncbi.nlm.nih.gov/pubmed/30357780 http://dx.doi.org/10.1055/s-0038-1673689

Ejemplares similares

Erratum: Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice
por: Weycker, Derek, et al.
Publicado: (2018)

Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis
por: Cohen, Alexander, et al.
Publicado: (2021)

Hospital Resource Utilization and Costs Associated With Warfarin Versus Apixaban Treatment Among Patients Hospitalized for Venous Thromboembolism in the United States
por: Deitelzweig, Steven, et al.
Publicado: (2018)

Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity
por: Cohen, Alexander, et al.
Publicado: (2021)

Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease
por: Cohen, Alexander T., et al.
Publicado: (2021)

Effectiveness and safety of apixaban vs warfarin among venous thromboembolism patients at high-risk of bleeding
por: Cohen, Alexander T., et al.
Publicado: (2022)

Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for Recurrences
por: Cohen, Alexander T., et al.
Publicado: (2023)

Discontinuation risk comparison among ‘real-world’ newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban
por: Lip, Gregory Y. H., et al.
Publicado: (2018)

Effectiveness and Safety of Apixaban Versus Warfarin Among Older Patients with Venous Thromboembolism with Different Demographics and Socioeconomic Status
por: Cohen, Alexander T., et al.
Publicado: (2021)

Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice: A propensity-matched analysis of 76,940 patients
por: Li, Xiaoyan, et al.
Publicado: (2017)

Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach
por: Li, Xiaoyan, et al.
Publicado: (2018)

Comparative Clinical and Economic Outcomes Associated with Warfarin Versus Apixaban in the Treatment of Patients with Venous Thromboembolism in a Large U.S. Commercial Claims Database
por: Guo, Jennifer D., et al.
Publicado: (2020)

Cost–effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients
por: Hallinen, Taru, et al.
Publicado: (2016)

Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real‐world” observational study in the United States
por: Lip, Gregory Y. H., et al.
Publicado: (2016)

Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep‐Vein Thrombosis as First‐Line Therapy (AMPLIFY) Trial
por: Liu, Xianchen, et al.
Publicado: (2015)

Safety and effectiveness of apixaban compared to warfarin in dialysis patients
por: Reed, Daniel, et al.
Publicado: (2018)

Apixaban/heparin/warfarin: Treatment failure: case report
Publicado: (2021)

Dual Anticoagulation With Warfarin and Apixaban: A Case Report
por: Parker, Kristen, et al.
Publicado: (2022)

1514. Mortality and Readmission in Adults during the First Year Following Hospitalization for Community-Acquired Pneumonia in the US
por: Sato, Reiko, et al.
Publicado: (2020)

Venous Thromboembolism While on Anticoagulation With Apixaban
por: Mazahreh, Farah, et al.
Publicado: (2021)

Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice
por: Weycker, Derek, et al.
Publicado: (2019)

Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation
por: Christersson, Christina, et al.
Publicado: (2019)

A comparison between warfarin and apixaban: A patient's perspective
por: Althemery, Abdullah U., et al.
Publicado: (2020)

Safety of apixaban and rivaroxaban compared to warfarin after cardiac surgery
por: Naik, Kushal D., et al.
Publicado: (2022)

1510. Infant Pneumonia and Subsequent Risk of Chronic Respiratory Disorders
por: Pelton, Stephen I, et al.
Publicado: (2020)

Apixaban for the treatment of cancer-associated venous thromboembolism and left atrial appendage thrombus refractory to optimal anticoagulation with warfarin: a case report
por: Koga, Masashi, et al.
Publicado: (2018)

Safety and effectiveness of apixaban versus warfarin for acute venous thromboembolism in patients with end‐stage kidney disease: A national cohort study
por: Ellenbogen, Michael I., et al.
Publicado: (2022)

Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation
por: Lee, Soyon, et al.
Publicado: (2012)

Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation
por: Bahit, M Cecilia, et al.
Publicado: (2017)

Apixaban vs. Warfarin in Atrial Fibrillation Patients With Chronic Kidney Disease
por: Fu, Chung-Ming, et al.
Publicado: (2021)

Comparing the Efficacy and Safety of Apixaban Versus Warfarin in Morbidly Obese Patients
por: Alotaibi, Sultan N, et al.
Publicado: (2022)

Real-World Effectiveness and Safety of Apixaban versus Warfarin in Patients with Acute Venous Thromboembolism: Experience of a Large Tertiary Hospital in Saudi Arabia
por: Al Yami, Majed S, et al.
Publicado: (2021)

Safety of apixaban for venous thromboembolism prophylaxis: the evidence to date
por: Trkulja, Vladimir
Publicado: (2016)

Apixaban/tocilizumab interaction: Venous thromboembolism: case report
Publicado: (2021)

Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
por: Wisløff, Torbjørn, et al.
Publicado: (2014)

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

Resolution of a warfarin and dabigatran-resistant left atrial appendage thrombus with apixaban
por: Miwa, Yosuke, et al.
Publicado: (2016)

Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation
por: Hallinen, Taru, et al.
Publicado: (2021)

1942. Potential Public Health Impact of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccine for Prevention of RSV among US Infants
por: Hanau, Ahuva, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b77fmf76601l6rc913rbos3mri